Repositori institucional URV
Español Català English
TITLE:
Patients who suffer a first atherosclerotic cardiovascular event while taking statins are often far off of lipid targets - imarina:9366508

URV's Author/s:Masana Marín, Luis
Author, as appears in the article.:Masana, L; de Isla, LP; Moya, GD
Author's mail:luis.masana@urv.cat
Author identifier:0000-0002-0789-4954
Journal publication year:2024
Publication Type:Journal Publications
APA:Masana, L; de Isla, LP; Moya, GD (2024). Patients who suffer a first atherosclerotic cardiovascular event while taking statins are often far off of lipid targets. Nutrition Metabolism And Cardiovascular Diseases, 34(1), 90-97. DOI: 10.1016/j.numecd.2023.09.022
Papper original source:Nutrition Metabolism And Cardiovascular Diseases. 34 (1): 90-97
Abstract:Background and aims: Despite considerable evidence that lipid-lowe ring therapies (LLTs) afford clinical benefit, the control of low-density lipoprotein cholesterol (LDL-C) is suboptimal, and available LLTs are underused, especially in patients at high and very high cardiovascular (CV) risk. This study assesses the real-world LDL-C target attainment rate in patients on LLT before experiencing a first major acute cardiovascular event (MACE). Methods and results: The HEARTBEAT was a retrospective, multicentre observational study. From March to June 2021 a total of 334 patients on LLT who had a first MACE while being on statins were included in the study. Of these patients, 83.2 % had a high (40.7 %) or very high CV risk (29.0 %) prior to MACE. Overall, 87.5 % and 89.7 % of the patients at high and very high CV risk, respectively, failed to reach the LDL-C target. Regarding LLTs, only 11.8 % and 19.6 % of the patients at high and very high risk had received high-intensity LLTs prior to MACE. It was estimated that if these patients had reached their recommended LDL-C targets, the risk of MACE may have been reduced by a median of 24.5 % and 23.2 % in patients at high and very high risk respectively. Conclusions: Patients who suffer a first MACE while on statin therapy often were at high/very high CV risk. Despite their risk, LDL-levels and being on statins they are undertreated, and too far from lipid targets. A proper use of high-intensity LLTs led to an increase attainment of LDL targets and lower CV events. (c) 2023 The Author(s). Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Article's DOI:10.1016/j.numecd.2023.09.022
Link to the original source:https://www.nmcd-journal.com/article/S0939-4753(23)00383-6/fulltext
Papper version:info:eu-repo/semantics/publishedVersion
licence for use:https://creativecommons.org/licenses/by/3.0/es/
Department:Medicina i Cirurgia
Licence document URL:https://repositori.urv.cat/ca/proteccio-de-dades/
Thematic Areas:Serviço social
Saúde coletiva
Nutrition and dietetics
Nutrition & dietetics
Nutrição
Medicine (miscellaneous)
Medicina veterinaria
Medicina iii
Medicina ii
Medicina i
Interdisciplinar
General medicine
Farmacia
Enfermagem
Endocrinology, diabetes and metabolism
Endocrinology & metabolism
Educação física
Ciências biológicas ii
Ciências biológicas i
Ciências ambientais
Cardiology and cardiovascular medicine
Cardiac & cardiovascular systems
Keywords:Spain
Safety
Risk
Primary prevention
Population
Participants
Metaanalysis
Lowering therapy
Low-density lipoprotein cholesterol
Lipid-lowering therapy
Ldl-cholesterol
Efficacy
Coronary-heart-disease
Cardiovascular risk
Entity:Universitat Rovira i Virgili
Record's date:2024-08-03
Search your record at:

Available files
FileDescriptionFormat
DocumentPrincipalDocumentPrincipalapplication/pdf

Information

© 2011 Universitat Rovira i Virgili